A panelist discusses how emerging investigational agents for NMIBC show promise through diverse mechanisms, including oncolytic viruses (CG0070), immune checkpoint inhibitors (durvalumab, sasanlimab), ...

"The interplay between the microbiome and bladder cancer is very complex," says Ilaha Isali, MD, MSc. Isali: The interplay between the microbiome and bladder cancer is very complex. There is still ...

“The key take home message of that study was that having assumptions about basic medical terminology that we think are simple may actually leave patients confused,” says Vikram M. Narayan, MD. In this ...

“Another aspect is how to make this more and more complex diagnostic chain for prostate cancer work in practice, because we now have so [many] more tools than we had a decade ago,” says Tobias ...

"Studying the microbiome overall is challenging because it's dirty science. You have to be incredibly careful with contamination," says Ilaha Isali, MD, MSc, and Laura Bukavina, MD, MPH, MSc. Isali: ...

Would you please start by giving a brief overview of BCG-unresponsive NMIBC? Nonmuscle Invasive Bladder Cancer Prior to recent therapeutic innovations in the bladder space what challenges or unmet ...

Enfortumab vedotin and pembrolizumab combination significantly improves overall and progression-free survival in advanced urothelial carcinoma compared to platinum-based chemotherapy. The EV-302 trial ...

Please review the standard treatment options (intravesical chemotherapy, PD-L1 inhibitors, other immunotherapeutic options) currently available for patients with BCG-unresponsive NMIBC.

CMS issued a J-code for Anktiva, effective January 1, 2025, aiding billing and reimbursement processes for intravesical therapies. Anktiva, approved by the FDA in April 2024, is used with BCG for ...

Bayer seeks approval in China for darolutamide plus ADT for mHSPC, marking a potential third indication. The ARANOTE trial showed darolutamide plus ADT significantly improved rPFS and OS compared to ...

"If we synergize our efforts and our energy, as the level of the sea rises, all ships on the sea will rise with it," says Wayne Kuang, MD. In this video, Wayne Kuang, MD, discusses the importance of ...

Erdafitinib received full FDA approval for FGFR3-positive urothelial carcinoma, demonstrating improved overall survival in the phase 3 THOR trial. Cefepime ...